Physical Therapists in Cannon Afb, NM Accepting Medicare
5 Physical Therapists found. Showing 1 - 5
 Dr. Taylor A Waters, PT,DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 224 W D. L. Ingram Avenue, Bldg 1408, Cannon Afb, NM 88103 Phone: 540-692-4484 |
 Dr. Taylor Gregory Majerus, PT, DPT, OCS, SCS Physical Therapist - Sports Medicare: Not Enrolled in Medicare Practice Location: 224 W D. L. Ingram Ave, Cannon Afb, NM 88101 Phone: 575-784-2778 |
Ashton Nanette Wedemeyer, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 124 N Aderholt Loop, Cannon Afb, NM 88103 Phone: 575-904-3506 |
Dr. Sarah Alicia Paulson, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 224 W D. L. Ingram Avenue, Bldg. 1408, Cannon Afb, NM 88103 Phone: 575-784-2778 |
Dr. Joseph A Williams, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 208 W Dl Ingram Ave, 27 Somdg, Cannon Afb, NM 88103 Phone: 575-784-4425 |
News Archive
Ingenuity Systems and Geospiza partner to enable seamless next-generation sequencing analysis workflow
Ingenuity® Systems, a leading provider of information solutions for life science researchers, and Geospiza, Inc., the market leading developer of laboratory management and genetic analysis software, today announced a collaboration to enable a seamless next-generation sequencing analysis workflow. The companies will integrate their software products, GeneSifter® and IPA®, to enable researchers to obtain deep biological insights from their project samples through a rapid and reliable workflow to analyze and visualize next-generation sequencing data.
Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C
All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.
Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.
› Verified 7 days ago